Biblio
Export 1190 results:
Author Title Type [ Year] Filters: First Letter Of Last Name is D [Clear All Filters]
“Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, and Regional Amyloid-β and Tau Pathology in Middle-Aged Adults: The Framingham Study.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1371-1383, 2022.
, “Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, and Regional Amyloid-β and Tau Pathology in Middle-Aged Adults: The Framingham Study.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1371-1383, 2022.
, “A Novel Panel of Plasma Proteins Predicts Progression in Prodromal Alzheimer's Disease.”, J Alzheimers Dis, vol. 88, no. 2, pp. 549-561, 2022.
, “Obesity-Associated Neurodegeneration Pattern Mimics Alzheimer's Disease in an Observational Cohort Study.”, J Alzheimers Dis, vol. 91, no. 3, pp. 1059-1071, 2022.
, “Obesity-Associated Neurodegeneration Pattern Mimics Alzheimer's Disease in an Observational Cohort Study.”, J Alzheimers Dis, vol. 91, no. 3, pp. 1059-1071, 2022.
, “The Outcome of Patients with Amyloid-Negative Amnestic Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 86, no. 2, pp. 629-640, 2022.
, “Plasma Cholesterol Levels as Potential Nutritional Biomarkers for Lewy Body Dementia.”, J Alzheimers Dis, vol. 86, no. 2, pp. 779-786, 2022.
, “Plasma Myeloperoxidase as a Potential Biomarker of Patient Response to Anti-Dementia Treatment in Alzheimer's Disease.”, J Alzheimers Dis, vol. 89, no. 4, pp. 1483-1492, 2022.
, “Post-Stroke Cognitive Impairment: Epidemiology, Risk Factors, and Management.”, J Alzheimers Dis, vol. 86, no. 3, pp. 983-999, 2022.
, “Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimer's Disease Neuropathology.”, J Alzheimers Dis, vol. 87, no. 1, pp. 51-81, 2022.
, “Pre-Diagnostic Symptoms of Young-Onset Dementia in the General Practice up to Five Years Before Diagnosis.”, J Alzheimers Dis, vol. 88, no. 1, pp. 229-239, 2022.
, “Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions.”, J Alzheimers Dis, vol. 88, no. 4, pp. 1203-1228, 2022.
, “Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions.”, J Alzheimers Dis, vol. 88, no. 4, pp. 1203-1228, 2022.
, “Rheumatoid Arthritis, Cognitive Impairment, and Neuroimaging Biomarkers: Results from the Mayo Clinic Study of Aging.”, J Alzheimers Dis, vol. 89, no. 3, pp. 943-954, 2022.
, “The Role of Amyloid, Tau, and APOE Genotype on the Relationship Between Informant-Reported Sleep Disturbance and Alzheimer's Disease Risks.”, J Alzheimers Dis, vol. 87, no. 4, pp. 1567-1580, 2022.
, “The Role of Amyloid-β, Tau, and α-Synuclein Proteins as Putative Blood Biomarkers in Patients with Cerebral Amyloid Angiopathy.”, J Alzheimers Dis, vol. 89, no. 3, pp. 1039-1049, 2022.
, “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1399-1413, 2022.
, “Salivary Proteomics Reveals Significant Changes in Relation to Alzheimer's Disease and Aging.”, J Alzheimers Dis, vol. 89, no. 2, pp. 605-622, 2022.
, “Single Nucleus Transcriptome Data from Alzheimer's Disease Mouse Models Yield New Insight into Pathophysiology.”, J Alzheimers Dis, vol. 90, no. 3, pp. 1233-1247, 2022.
, “The Spectrum of Alzheimer-Type Pathology in Cognitively Normal Individuals.”, J Alzheimers Dis, vol. 91, no. 2, pp. 683-695, 2022.
, “Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer's Disease.”, J Alzheimers Dis, vol. 88, no. 4, pp. 1627-1637, 2022.
, “Accelerometer-Measured, Habitual Physical Activity and Circulating Brain-Derived Neurotrophic Factor: A Cross-Sectional Study.”, J Alzheimers Dis, vol. 85, no. 2, pp. 805-814, 2021.
, “APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 79, no. 2, pp. 511-530, 2021.
, “Apolipoprotein E ɛ4 (APOE ɛ4) Allele is Associated with Long Sleep Duration Among Elderly with Cognitive Impairment.”, J Alzheimers Dis, vol. 79, no. 2, pp. 763-771, 2021.
, “Association of Midlife Depressive Symptoms with Regional Amyloid-β and Tau in the Framingham Heart Study.”, J Alzheimers Dis, vol. 82, no. 1, pp. 249-260, 2021.
,